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■ Abstract 
OBJECTIVES: Elevated homocysteine levels are considered 
to be an independent risk factor for cardiovascular compli-
cations in diabetic patients. The aim of this study was to find 
out if zinc supplementation improves homocysteine levels, 
which may exert vascular-protective effects in type 2 diabe-
tes subjects with microalbuminuria. METHODS: In a ran-
domized, double-blind, controlled, crossover study, 50 type 
2 diabetic patients with microalbuminuria were subdivided 
into two groups and supplemented with 30 mg/d of zinc 
(group 1) or placebo (group 2) for three months with a four-
week wash out period. Serum creatinine, vitamin B12, folate, 
fasting plasma glucose, HbA1c, lipid profiles, zinc, homo-
cysteine levels and random urine albumin were measured 
before and after the first and second phase of the study in all 
participants. RESULTS: Mean serum zinc was significantly 
increased after zinc supplementation (from 76 ± 16 µg/dl to 
93 ± 20 µg/dl; p < 0.05), while there was no change in the 
placebo group (75 ± 16 µg/dl to 75 ± 15 µg/dl). With zinc 
supplementation, homocysteine levels reduced significantly 
(from 13.71 ± 3.84 µmol/l to 11.79 ± 3.06 µmol/l; p < 
0.05), which did not occur on placebo (from 12.59 ± 2.13 
µmol/l to 13.36 ± 2.03 µmol/l). Simple regression was used 
to show a positive correlation between urine albumin excre-
tion and serum homocysteine (r = 0.37, p = 0.023). Vitamin 
B12 and folate levels increased significantly in patients who 
received zinc in comparison to those who received placebo. 
A negative correlation was observed between homocysteine 
and vitamin B12 concentration (r = -0.36, p = 0.025). CON-
CLUSION: Zinc supplementation reduced serum homocys-
teine and increased vitamin B12 and folate concentrations in 
type 2 diabetic patients with microalbuminuria. 
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Introduction  
 
 iabetes mellitus (DM) is a chronic disease char- 
 acterized by hyperglycemia and disorders in the 
 metabolism of carbohydrates, lipids and several 
essential trace elements [1]. The status of certain essen-
tial trace elements, such as Zn, Cu, Cr, Mn and Mg, 
has already been investigated in patients with type 2 
DM [1-3]. 
Zinc (Zn) forms part of many protein domains, 
such as zinc metaloenzymes, and is involved in the 
synthesis, storage and secretion of insulin monomers 
[1, 4]. It is considered to be deficient if serum zinc is 
less than 60 µg/dl [5]. Diabetes is usually accompanied 
by zincuria and consumption of nutritional supple-
ments can substantially increase zinc absorption by the 
gastrointestinal tract [6]. However, the effects of sup-
plemental zinc, if dietary intake is adequate, are incom-
pletely understood. More clinical data on diabetic pa-
tients who are at increased risk of zinc deficiency 
would be helpful as zinc has an insulinomimetic effect 
and protects against the oxidative damage associated 
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with the disease [7, 8]. In addition, in diabetic patients, 
oxidative damage may result in lower antioxidant mi-
cronutrient status, especially trace elements [9]. Ab-
normal serum Zn status, therefore, can promote the 
progression of diabetes [2, 10, 11]. 
In diabetic patients, microalbuminuria is a major 
factor which predicts the onset of overt renal disease 
and reflects glomerular dysfunction [12]. Zinc supple-
mentation has beneficial effects on microalbuminuria 
and serum lipid profile in type 2 DM with microalbu-
minuria, as we have reported previously [13]. In the 
present study, we examined the effects of zinc on se-
rum homocysteine levels in the same population. Ho-
mocysteine (hCys) is a sulfure-containing amino acid 
produced by demethylation of methionine (an essential 
amino acid) [14]. Glomerular filtration rate may be im-
paired in individuals with type 2 DM [15] and is a ma-
jor factor in increasing plasma homocysteine concen-
tration [16, 17]. Elevated homocysteine levels are toxic 
to the vascular endothelium [18]. They result in endo-
thelial dysfunction, promote proliferation of vascular 
smooth muscle, increase low-density lipoprotein per-
oxidation and platelet activation and are considered to 
be an independent risk factor for cardiovascular dis-
ease in diabetic [19-23] and non-diabetic persons [24-
26]. 
Two major vitamins, B12 and folate, are needed to 
convert hCys to methionine (Met) by the remethyla-
tion reaction [27, 28]. Therefore, folate and vitamin B12 
deficiency can impair methionine synthesis. Accord-
ingly, a reduction in methylene tetrahydrofolate reduc-
tase enzyme activity can cause subsequent homocys-
teine accumulation in the plasma [29, 30]. It has been 
shown that redox-reactive compounds can influence 
the activity of enzymes involved in hCys and Met me-
tabolism, especially betaine-homocysteine methyltrans-
ferase (BHMT) and methionine synthase (MetH, re-
methylated hCys to methionine) [31, 32]. These en-
zymes are zinc metalloenzymes [33, 34]. So, changes in 
serum Zn levels, especially its deficiency, can influence 
the activity of the above-mentioned enzymes and sub-
sequently increase serum hCys level. 
To the best of our knowledge, there are no reports 
about the effects of Zn supplementation on serum 
hCys levels in type 2 DM with microalbuminuria. As 
both microalbuminuria and hCys are known risk fac-
tors for cardiovascular diseases in diabetic patients and 
hCys metabolism is related to zinc status, the aim of 
this study was to determine the effects of Zn supple-
mentation on serum hCys level and to investigate the 
correlation between serum hCys level and albuminuria 
in type 2 DM with microalbuminuria. 
Research design and methods 
In a randomized, double-blind, crossover and pla-
cebo-controlled clinical trial, 50 type 2 diabetic patients 
with microalbuminuria were subdivided into two 
groups and supplemented with 30 mg/d zinc (group 1) 
or placebo (group 2) for three months with a four-
week wash out period. The dosage of zinc was consis-
tent with that administered in other studies [11, 14]. 
Patients and procedures have been described in detail 
in our previous report [13]. 
The patients were frequently contacted by tele-
phone by one of our colleagues in the Isfahan Endo-
crine and Metabolism Research Center to monitor 
their compliance in taking medications. Forty five days 
after administering the medications (zinc or placebo), 
the patients were visited and interviewed to elicit pos-
sible side effects and to determine their degree of 
compliance [13]. The IEMRC Medical Ethics Commit-
tee approved the study protocol, and all participants 
provided written consent. The research complied with 
the current version of the Declaration of Helsinki. 
Laboratory assessments 
After a 12 h overnight fast, venous blood and urine 
samples were collected from all patients before any 
medication was taken. Serum and urine samples were 
 
 
Table 1. Comparison of serum zinc, folate, vitamin B12 and homocysteine in type 2 diabetic patients with microalbuminuria before 
and after treatment with zinc (first phase) and placebo (second phase) in group 1 
 
 
Parameter 
 
Zinc (n = 21) 
 
     Before treatment          After treatment 
  
Placebo (n = 18)  
 
 Before treatment           After treatment 
 
Serum zinc (µg/dl) 76.
 
00 
 
± 16.
 
00 93.
 
00
 
± 
 
20.
 
00* 
 
75.
 
00
 
± 
 
16.
 
00 
 
75.
 
00 
 
± 
 
15.
 
00 
 
Folate (ng/ml) 9.
 
71 
 
± 1.
 
80 12.
 
87
 
± 
 
3.
 
01* 
 
12.
 
60
 
± 
 
1.
 
59 
 
10.
 
50 
 
± 
 
1.
 
36 
 
Vitamin B12 (pg/ml) 495.
 
75 
 
± 163.
 
33 549.
 
89
 
± 
 
106.
 
52* 
 
510.
 
77
 
± 
 
133.
 
50 
 
498.
 
10 
 
± 
 
119.
 
18 
 
Homocysteine (µmol/l) 13.
 
71 
 
± 3.
 
84 11.
 
79
 
± 
 
3.
 
06* 
 
12.
 
95
 
± 
 
2.
 
13 
 
13.
 
36 
 
± 
 
2.
 
03 
 
Legend: Data are mean ± SD. Group 1: first phase zinc (3 months), second phase placebo (3 months), 4 weeks wash-out in-between. * p < 0.05. 
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analyzed on the same day for all the variables except 
for serum zinc, vitamin B12, folate and hCys levels. To 
measure these parameters, serum samples were stored 
at -70°C at the IEMRC laboratory and assayed at the 
end of each study phase. Vitamin B12 and folate were 
measured using a radioimmunoassay (RIA) kit (Di-
asorin, USA). An enzyme immunoassay (EIA) kit 
(Axis-Shield Diagnostic, UK) was used to measure 
homocysteine (free and protein bound). Other labora-
tory methods applied in the study have been explained 
in detail in our previously published report [13]. 
Statistical analysis 
Kolmogorov and Smirnov tests were used for de-
pendent and independent variables to assess the nor-
mality of the variables prior to further statistical analy-
sis. A paired t-test was used to compare the mean of 
variables before and after zinc supplementation in each 
group. Student’s t-test was used to compare the vari-
ables between two independent groups before and af-
ter each study phase. The Pearson correlation coeffi-
cient was used to determine the relationship between 
serum zinc or homocysteine with urinary albumin ex-
cretion and serum vitamin B12 with homocysteine con-
centration. It was decided to consider p-values less 
than 0.05 to be statistically significant. Statistical analy-
sis of the data was performed using the Statistics Pack-
age for Social Science (SPSS version 13.0, SPSS Inc., 
Chicago, IL, USA). 
Results 
Demographic characteristics, systolic and diastolic 
blood pressure, serum lipids, HbA1c, fasting plasma 
glucose, urinary albumin excretion and serum zinc 
concentration, at the beginning and end of each phase 
have been reported in our previous paper [13]. We re-
port here on additional effects of zinc supplementation 
on serum homocysteine levels in type 2 DM patients 
to verify possible protective effects on vasculature. 
Effects of zinc supplementation on serum zinc level 
At baseline in the first phase, serum Zn levels were 
similar in both groups before supplementation (Tables 
1 and 2). In the first and second phase, serum Zn lev-
els increased in both groups receiving supplemental Zn 
(p < 0.05). There was no significant change in Zn lev-
els in the placebo-treated groups (Tables 1 and 2) at 
the first and second phase of the study. A negative sig-
nificant correlation (r = -0.34, p = 0.037) was observed 
between urinary albumin excretion and serum Zn level 
(Figure 1A). 
Effects of zinc supplementation on serum hCys levels 
Serum hCys levels also reduced significantly at the 
end of the first phase in group 1 (zinc supplementa-
tion) compared to the second phase (hCys: 11.79 ± 
3.06 µmol/l vs.13.36 ± 2.03 µmol/l) (Table 1). Figure 
2A compares serum hCys levels in type 2 diabetic pa-
tients before and after administration of Zn or placebo 
in group 1 and 2. A positive significant correlation (r = 
0.37, p = 0.023) was found between urinary albumin 
excretion and serum hCys level (Figure 1B). 
Effects of zinc supplementation on serum folate and vitamin B12 
levels 
As shown in Table 1 and Figure 2B, folate and vi-
tamin B12 significantly increased (p < 0.05) in the first 
phase in group 1 (Zn supplementation) in comparison 
to the second phase (folate: 12.87 ± 3.01 ng/ml vs. 
10.50 ± 1.38 ng/ml and vitamin B12: 549.89 ± 106.52 
pg/ml vs. 498.10 ± 119.18 pg/ml). In group 2 (patients 
who received placebo in the first phase and zinc in the 
second phase), serum levels of folate and vitamin B12 
did not significantly change at the end of the first 
phase (Table 2 and Figure 2B). In addition, an inverse 
correlation was found between serum hCys and vita-
min B12 levels (r = -0.36, p = 0.025) (Figure 3), while 
Table 2. Comparison of serum zinc, folate, vitamin B12 and homocysteine in type 2 diabetic patients with microalbuminuria before 
and after treatment with placebo (first phase) and zinc (second phase) in group 2 
 
 
Parameter 
 
Placebo (n = 21) 
 
     Before treatment          After treatment 
  
Zinc (n = 21)  
 
 Before treatment           After treatment 
 
Serum zinc (µg/dl) 73.
 
00 
 
± 16.
 
00 75.
 
00
 
± 
 
14.
 
00 
 
75.
 
50
 
± 
 
11.
 
00 
 
95.
 
00 
 
± 
 
22.
 
00* 
 
Folate (ng/ml) 9.
 
32 
 
± 1.
 
56 9.
 
92
 
± 
 
1.
 
87 
 
10.
 
57
 
± 
 
1.
 
34 
 
12.
 
92 
 
± 
 
1.
 
58* 
 
Vitamin B12 (pg/ml) 438.
 
24 
 
± 102.
 
70 462.
 
00
 
± 
 
22.
 
00 
 
464.
 
93
 
± 
 
26.
 
00 
 
591.
 
48 
 
± 
 
130.
 
61* 
 
Homocysteine (µmol/l) 13.
 
46 
 
± 3.
 
96 13.
 
48
 
± 
 
3.
 
68 
 
14.
 
86
 
± 
 
3.
 
72 
 
12.
 
89 
 
± 
 
2.
 
49* 
 
Legend: Data are mean ± SD. Group 2: first phase placebo (3 months), second phase zinc (3 months), 4 weeks wash-out in-between. * p < 0.05. 
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no significant relationship was observed between se-
rum folate and hCys concentration. 
Discussion 
Clinical research suggests that the homeostasis of 
essential trace elements, especially zinc, can be dis-
rupted by diabetes mellitus [1, 6, 35, 36]. Our data 
showed that zinc supplementation causes an increase 
in serum Zn level, as reported in other studies [4, 37]. 
This finding proved the good compliance shown by 
our patients in taking zinc supplementation. 
Previous reports have demonstrated beneficial ef-
fects of zinc supplementation on the burden of oxida-
tive stress [38, 39], retinopathy [40-42] and on the re-
duction in microalbuminuria in subjects with type 2 
DM [13]. In type 2 DM with proteinuria or renal insuf-
ficiency, hCys usually increases [43, 44] and is an inde-
pendent risk factor for arteriosclerosis in both diabetic 
and cardiac patients [38, 45]. Several studies have al-
ready investigated the correlation between serum hCys 
level and cardiovascular outcomes in type 2 DM [22, 
38]. In normal subjects, but not in type 2 DM, insulin 
may play a role in hCys metabolism. Another finding is 
that hyperinsulinemia decreases serum hCys concentra-
tion [30]. 
It was found that insulin resistance in type 2 DM is 
associated with abnormalities in renal function and 
leads to an elevation in the hCys level that may finally 
cause subclinical renal dysfunction [46]. Moreover, it 
has been reported that hyperhomocysteinemia predicts 
the development of microalbuminuria in type 2 DM 
[47], and that supplemental Zn can improve the serum 
hCys level. It was therefore interesting to find out if 
Zn supplementation can reduce hCys levels in type 2 
DM patients with microalbuminuria and thus posi-
tively affect albuminuria in these patients. We found 
that the consumption of Zn has a beneficial effect in 
that it improves serum hCys level and decreases both 
hCys concentration and albumin excretion in type 2 
DM (Figure 2A, Table 1 and Table 2). 
The effect of supplemental Zn on serum hCys con-
centration may be due to an influence on BHMT and 
methionine synthase (MetH) enzymes which convert 
hCys to Met in mammals and thereby exert important 
effects on the cellular and plasma levels of hCys [31, 
33]. These enzymes are zinc metalloenzymes, which 
suggests that cysteine residues are involved in the zinc 
binding site of these enzymes. Zn is required for the 
binding of hCys to BHMT [33, 34]. It was shown that 
zinc ions activate hCys for its conversion to methion-
ine [48]. BHMT is a key liver enzyme which is impor-
tant for hCys homeostasis and accounts for approxi-
mately half of the methionine synthesized in the liver 
[33]. There is evidence that some of the zinc-
dependent enzymes activating alkyl transfer to thiols, 
especially BHMT and MetH, are prone to oxidative 
inactivation and loss of zinc. Inactivation has been as-
sumed to involve formation of a disulfide incorporat-
ing at least one of the cysteine ligands to zinc [48]. Cas-
tro et al. have shown that incubation of BHMT with 
oxidant agents can release Zn from the active site of 
the enzyme [32]. The presence of zinc as a component 
of the oxidant defense system is supported by findings 
obtained from studies conducted in animal and cell 
models, which indicate that zinc deficiency induces 
oxidative damage to cell components and alterations in 
antioxidant enzymes [39]. As zincuria is observed in 
diabetes mellitus, Zn deficiency could lead to inactiva-
tion of the above mentioned enzymes. Zn supplemen-
tation in diabetic patients increases plasma Zn level 
and probably promotes BHMT and MetH activity to 
decrease the plasma hCys level. 
Homocysteine metabolism is dependent on the 
concentrations of B vitamins; that is, folate, serum vi-
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Figure 1. Correlation between serum zinc (A) and homo-
cysteine (B) levels with urine albumin excretion in diabetic 
patients with microalbuminuria. Each individual value is 
represented by a dot. r = Pearson correlation coefficient. 
 
 
68  The Review of Diabetic Studies Heidarian, Amini, et al. 
  Vol. 6 ⋅ No. 1 ⋅ 2009 
 
Rev Diabet Stud (2009) 6:64-70  Copyright © by the SBDR 
tamin B12 and vitamin B6 status, which may play some 
part in the cardiovascular events mediated by hCys 
plasma concentrations [49]. Low circulating folate and 
vitamin B12 concentrations lead to high fasting total 
homocysteine concentrations in humans [50]. In turn, 
elevated fasting total homocysteine concentrations are 
usually normalized by administration of vitamin B12 
and folic acid [50, 51]. In our study, vitamin B12 and 
folate levels were within the normal range at the be-
ginning of the study. Zn supplementation, however, 
led to a significant rise in serum levels, which are im-
portant for hCys metabolism. Moreover, our results 
showed an inverse correlation between serum hCys 
and vitamin B12 in the groups given supplemental Zn 
(Figure 3), which has already been observed by other 
investigators [52-54]. The increased vitamin B12 and 
folate in our study is probably due to a reduction in se-
rum hCys brought about by an elevated plasma Zn 
level, which promotes BHMT and MetH activity to 
decrease plasma hCys level. 
It has also been demonstrated that hyperhomocys-
teinemia can be associated with albuminuria and renal 
failure [16, 17]. Therefore, urinary albumin excretion 
rates correlate with fasting plasma hCys concentration. 
In patients with diabetes and microalbuminuria, fasting 
hCys concentrations are higher than they are 
in those with normal albumin excretion. On 
the other hand, Zn supplementation re-
sulted in the reduction of microalbuminuria 
in subjects with type 2 diabetes [13]. There-
fore, we conclude that the increased levels 
of serum vitamin B12 and folate in the pre-
sent study resulted from the decreased al-
bumin excretion and promotion of BHMT 
and MetH activity brought about by Zn 
supplementation. 
With the present study, we have shown 
that Zn supplementation improves the hCys 
and albumin profile of diabetic patients with 
microalbuminuria. However, we do not 
know if positive effects on vascular inflam-
mation or insulin capacity could play critical 
roles in the underlying biological mecha-
nisms. The measurement of inflammatory 
markers, such as highly sensitive C-reactive 
protein (HS-CRP), IL-6 and fibrinogen, 
could shed some light on this question. 
These measurements were not taken into 
consideration, which limits the explanatory 
power of our study in this regard. Nor did 
we perform IVGTT, which could supply in-
formation about the patients’ insulin capac-
ity. IVGTT could help to determine if Zn supplemen-
tation has an insulinomimetic effect, which may in part 
be due to decreased homocysteine levels. Therefore, 
we recommend to include IVGTT and inflammatory 
markers in future studies. 
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Figure 2. Serum homocysteine (A) and vitamin B12 (B) levels in 
type 2 diabetic patients with microalbuminuria before and after 
treatment with zinc or placebo in group 1 and group 2. Group 1 
received zinc in the first and placebo in the second phase, while 
group 2 received placebo in the first and zinc in the second 
phase. * p < 0.05. 
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Figure 3. Correlation between serum homocysteine level 
and vitamin B12 in type 2 diabetic patients with microalbu-
minuria. Each individual value is represented by a dot. r = 
Pearson correlation coefficient. 
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Conclusion 
Supplemental zinc decreases serum hCys and in-
creases serum vitamin B12 and folate in type 2 diabetic 
patients with microalbuminuria. Therefore, zinc sup-
plementation may be used to decrease hCys in type 2 
DM with microalbuminuria. 
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